



29. A compound of formula I:



wherein R^1 and R^2 independently represent

- (i) $-C_{1-6}$ alkyl, $-C_{3-8}$ cycloalkyl or $-C_{1-3}$ alkyl C_{3-8} cycloalkyl, or such a group in which alkyl or cycloalkyl is substituted by one or more halogen, -CN, nitro, hydroxy or $-OC_{1-6}$ alkyl groups;
- (ii) $-(CH_2)_6Ar^1$ or $-(CH_2)_6OAr^1$;
- or NR^1R^2 together represent pyrrolidinyl, piperidinyl, piperazinyl, thiomorpholinyl, morpholinyl or azepinyl, or such a group fused to a benzene ring, optionally substituted by one or more $-(CO)_n(CH_2)_tAr^1$, $-(CO)_nC_{1-6}$ alkyl Ar^1Ar^2 , $-(CO)_nC_{1-6}$ alkyl, $-(CH_2)_rOH$, $-(CH_2)_rO(CH_2)_pOH$, $-(CH_2)_rOC_{1-6}$ alkyl, $-O(CH_2)_tAr^1$, $-(CH_2)_rSO_2Ar^1$, piperidin-1-yl, $-(CH_2)_tCONR^8R^9$, $-NR^{10}(CO)_n(CH_2)_tAr^1$, $-NR^{10}(CO)_nC_{1-3}alkylC_{3-6}$ cycloalkyl, $-NR^{10}(CO)_nC_{1-6}$ alkyldi C_{3-6} cycloalkyl, $-CONR^{10}(CH_2)_tAr^1$, halogen, $-NHSO_2C_{1-6}alkyl$, $-SO_2NR^{10}R^{11}$, $-SO_2C_{1-6}$ alkyl or $-SO_2Ar^2$ groups;
- R^3 represents $-C_{1-6}alkylNHC(=NH)NH_2$, $-C_{2-6}alkenylNHC(=NH)NH_2$, $-C_{2-6}alkynylNHC(=NH)NH_2$, $-C_{1-6}alkylNR^{14}R^{18}$, $-(CH_2)_hCONR^{14}R^{18}$, $-(CH_2)_hCOC_{1-6}alkyl$, $-(CH_2)_dCHNR^{18}CONR^{20}R^{21}$, $-(CH_2)_mNR^{18}CONR^{14}R^{18}$, $-(CH_2)_dNR^{18}Ar^3$, $-(CH_2)_dCONR^{18}Ar^3$, $-(CH_2)_hCOOR^{18}$, $-(CH_2)_cAr^3$, $-O(CH_2)_cAr^3$, $-(CH_2)_dCO(CH_2)_sAr^3$ or $-(CH_2)_dOAr^3$;
- or R^3 represents $-(CH_2)_c$ -2,4-imidazolidinedione, $-(CH_2)_c$ (piperidin-4-yl), $-(CH_2)_c$ (piperidin-3-yl), $-(CH_2)_c$ (piperidin-2-yl), $-(CH_2)_c$ (morpholin-3-yl) or $-(CH_2)_c$ (morpholin-2-yl) optionally substituted on nitrogen by $-(CO)_tC_{1-6}alkyl$, $-(CO)_t(CH_2)_cAr^2$ or $-C(=NH)NH_2$;
- or R^3 represents $-(CH_2)_z$ dibenzofuran optionally substituted by $-C_{1-6}alkyl$ or halogen;
- or R^3 represents $-(CH_2)_c$ -thioxanthen-9-one;
- R^4 represents hydrogen, $-C_{1-6}$ alkyl, $-C_{1-3}$ alkyl C_{3-6} cycloalkyl, $-(CH_2)_qAr^2$, $-C_{1-4}alkyl-X-R^7$, $-C_{1-4}alkyl SO_2C_{1-4}$ alkyl, $-C_{1-6}alkylNR^{12}R^{13}$ or $-C_{1-6}$ alkyl $NR^{12}COC_{1-6}$ alkyl;
- R^5 represents hydrogen, or R^4R^5 together with the carbon to which they are attached form a C_{5-7} cycloalkyl ring;

[illegible][illegible][illegible][illegible][illegible][illegible][illegible][illegible][illegible][illegible][illegible][illegible]

39. A compound of formula (I) which is:

(2S)-2-(((2S)-2-{[2-(2-Benzoylphenoxy)acetyl]amino}-4-methyl pentanoyl)amino)-3-{4-
[({4-[(2-phenylacetyl)amino]-1-piperidiny]carbonyl) oxy]phenyl}propanoic acid;
(2S)-2-(((2S)-4-Methyl-2-{[2-{[3-(1-piperidinylcarbonyl)-2-naphthyl]
oxy]acetyl}amino]pentanoyl)amino)-3-{4-[(4-[(2-phenylacetyl)amino]-1-
piperidinyl)carbonyl]oxy]phenyl}propanoic acid;
(2S)-3-{4-[(4-[(2,2-Dicyclohexylacetyl)amino]-1-piperidinyl)carbonyl) oxy]phenyl}-2-
{[(2S)-4-methyl-2-{[2-[4-(1-piperidinylcarbonyl)phenoxy]acetyl}
amino]pentanoyl]amino}propanoic acid;
(2S)-2-(((2S)-4-Methyl-2-{[2-[4-(1-piperidinylcarbonyl)phenoxy]
acetyl]amino}pentanoyl)amino)-3-{4-[(4-morpholinylcarbonyl)oxy]phenyl} propanoic
acid;
(2S)-3-{4-[(4-[(4-Aminocarbonyl)-1-piperidinyl]carbonyl)oxy]phenyl}-2-(((2S)-4-methyl-2-
{[2-[4-(1-piperidinylcarbonyl)phenoxy]acetyl]amino}pentanoyl) amino}propanoic acid;
(2S)-3-{4-[(4-[(2-Cyclohexylacetyl)amino]-1-piperidinyl)carbonyl) oxy]phenyl}-2-
[[(2S)-2-{[2-(2-iodophenoxy)acetyl]amino}-4-methylpentanoyl) amino]propanoic acid;
(2S)-3-{4-[(4-[(2,2-Dicyclohexylacetyl)amino]-1-piperidinyl)carbonyl) oxy]phenyl}-2-
[[(2S)-2-{[2-(2-iodophenoxy)acetyl]amino}-4-methylpentanoyl) amino]propanoic acid;
(2S)-2-(((2S)-2-[(Dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methyl pentanoyl)amino)-
3-{4-[(4-morpholinylcarbonyl)oxy]phenyl}propanoic acid;
(2S)-2-(((2S)-2-[(Dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methyl pentanoyl)amino)-
3-{4-[(4-[(2-phenylacetyl)amino]-1-piperidinyl)carbonyl]oxy] phenyl}propanoic acid;
(2S)-2-(((2S)-2-{[2-(2-iodophenoxy)acetyl]amino}-4-methyl pentanoyl)amino)-3-{4-
[({4-[(2-phenylacetyl)amino]-1-piperidinyl)carbonyl]oxy] phenyl}propanoic acid;
(2S)-3-(4-[(4-Acetyl-1-piperazinyl)carbonyl]oxy}phenyl)-2-(((2S)-2-{[2-(2-
iodophenoxy)acetyl]amino}-4-methylpentanoyl)amino]propanoic acid;
(2S)-3-(4-[(4-Benzoyl-1-piperazinyl)carbonyl]oxy}phenyl)-2-(((2S)-2-{[2-(2-
iodophenoxy)acetyl]amino}-4-methylpentanoyl)amino]propanoic acid;
(2S)-3-(4-[(4-Benzoyl-1-piperazinyl)carbonyl]oxy}phenyl)-2-(((2S)-2-{[2-(2,4-
dichlorophenoxy)acetyl]amino}-4-methylpentanoyl)amino]propanoic acid;
(2S)-3-{4-[(4-[(4-Aminocarbonyl)-1-piperidinyl]carbonyl)oxy]phenyl}-2-(((2S)-2-{[2-(2-
iodophenoxy)acetyl]amino}-4-methylpentanoyl)amino]propanoic acid;
(2S)-2-(((2S)-2-{[2-[2-(Tert-butyl)phenoxy]acetyl]amino}-4-methyl pentanoyl)amino)-
3-{4-[(4-[(1-piperidinylcarbonyl)-1-piperidinyl]carbonyl]oxy) phenyl}propanoic acid;

(2S)-2-(((2S)-4-Methyl-2-([2-(2-methylphenoxy)acetyl]amino) pentanoyl)amino)-3-[4-
 ([[4-(1-piperidinylcarbonyl)-1-piperidinyl]carbonyl]oxy) phenyl]propanoic acid;
 (2S)-2-(((2S)-2-((Dibenzo[b,d]furan-4-ylcarbonyl)amino)-4-methyl pentanoyl)amino)-
 3-[4-([[4-(1-piperidinylcarbonyl)-1-piperidinyl]carbonyl]oxy) phenyl]propanoic acid;
 (2S)-2-(((2S)-2-([2-((1-Bromo-2-naphthyl)oxy)acetyl]amino)-4-
 methylpentanoyl)amino)-3-[4-([[4-(1-piperidinylcarbonyl)-1-piperidinyl]carbonyl]
 oxy)phenyl]propanoic acid;
 (2S)-2-(((2S)-2-([2-([2-(Tert-butyl)phenoxy]acetyl]amino)-4-methyl pentanoyl)amino)-
 3-(4-([4-((4-fluorobenzyl)amino)carbonyl]-1-piperidinyl)
 carbonyl]oxy)phenyl]propanoic acid;
 (2S)-2-(((2S)-2-([2-(2,4-Dichlorophenoxy)acetyl]amino)-4-methyl pentanoyl)amino)-3-
 {4-[(4-morpholinylcarbonyl)oxy]phenyl}propanoic acid;
 (2S)-2-(((2S)-2-([2-(2-Benzoylphenoxy)acetyl]amino)-4-methyl pentanoyl)amino)-3-{4-
 [(4-morpholinylcarbonyl)oxy]phenyl}propanoic acid;
 (2S)-2-(((2S)-4-Methyl-2-([2-(2-propylphenoxy)acetyl]amino) pentanoyl)amino)-3-{4-
 [(4-morpholinylcarbonyl)oxy]phenyl}propanoic acid;
 (2S)-2-(((2S)-2-([2-((1-Bromo-2-naphthyl)oxy)acetyl]amino)-4-
 methylpentanoyl)amino)-3-{4-[(4-morpholinylcarbonyl)oxy]phenyl}propanoic acid;
 (2S)-2-(((2S)-2-([2-((Benzyloxy)carbonyl]amino)-4-methylpentanoyl) amino)-3-{4-[(4-
 morpholinylcarbonyl)oxy]phenyl}propanoic acid;
 (2S)-3-[4-([4-([2-(2-Furoyl)-1-piperazinyl]carbonyl]oxy)phenyl]-2-(((2S) -2-([2-(2-
 iodophenoxy)acetyl]amino)-4-methylpentanoyl)amino]propanoic acid;
 (2S)-2-(((2S)-2-([2-(2-Cyclohexylphenoxy)acetyl]amino)-4-methyl pentanoyl)amino)-
 3-[4-([4-([2-(2-furoyl)-1-piperazinyl]carbonyl]oxy)phenyl] propanoic acid;
 (2S)-2-(((2S)-2-([2-((1-Bromo-2-naphthyl)oxy)acetyl]amino)-4-
 methylpentanoyl)amino)-3-[4-([4-([2-(2-furoyl)-1-piperazinyl]carbonyl]oxy)phenyl]
 propanoic acid;
 (2S)-3-(4-([4-([2-(4-Chlorophenyl)acetyl]amino)-1-piperidinyl) carbonyl]oxy)phenyl)-
 2-(((2S)-2-([2-(2-cyclohexylphenoxy)acetyl]amino)-4-
 methylpentanoyl)amino]propanoic acid;
 (2S)-2-(((2S)-2-([2-(2-Benzoylphenoxy)acetyl]amino)-4-methyl pentanoyl)amino)-3-(4-
 ([[4-([2-(4-chlorophenyl)acetyl]amino)-1-piperidinyl) carbonyl]oxy]phenyl]propanoic
 acid;
 (2S)-3-(4-([4-([2-(4-Chlorophenyl)acetyl]amino)-1-piperidinyl) carbonyl]oxy)phenyl)-
 2-(((2S)-2-([2-(2-iodophenoxy)acetyl]amino)-4-methyl pentanoyl)amino]propanoic
 acid;

(2S)-2-(((2S)-2-((2-[2-(Tert-butyl)phenoxy]acetyl)amino)-4-methyl pentanoyl)amino)-3-(4-(((4-((2-(4-chlorophenyl)acetyl)amino)-1-piperidinyl) carbonyl)oxy)phenyl)propanoic acid;

(2S)-3-(4-(((4-((2-(4-Chlorophenyl)acetyl)amino)-1-piperidinyl) carbonyl)oxy)phenyl)-2-(((2S)-2-((dibenzo[b,d]furan-4-ylcarbonyl)amino)-4-methylpentanoyl)amino)propanoic acid;

(2S)-3-(4-(((4-((2-(4-Chlorophenyl)acetyl)amino)-1-piperidinyl) carbonyl)oxy)phenyl)-2-(((2S)-4-methyl-2-((2-((3-(1-piperidinylcarbonyl)-2-naphthyl)oxy)acetyl)amino)pentanoyl)amino)propanoic acid;

(2S)-2-(((2S)-2-((2-[2-(Tert-butyl)phenoxy]acetyl)amino)-4-methyl pentanoyl)amino)-3-(4-(((4-((2-cyclohexylacetyl)amino)-1-piperidinyl)carbonyl) oxy)phenyl)propanoic acid;

(2S)-2-(((2S)-2-((2-[2-(Tert-butyl)phenoxy]acetyl)amino)-4-methyl pentanoyl)amino)-3-(4-(((4-((2,2-dicyclohexylacetyl)amino)-1-piperidinyl) carbonyl)oxy)phenyl)propanoic acid;

(2S)-2-(((2S)-4-Methyl-2-((2-(2-methylphenoxy)acetyl)amino) pentanoyl)amino)-3-(4-(((4-((2-phenylacetyl)amino)-1-piperidinyl)carbonyl) oxy)phenyl)propanoic acid;

(2S)-2-(((2S)-2-((2-(2-Cyclohexylphenoxy)acetyl)amino)-4-methyl pentanoyl)amino)-3-(4-(((4-((2-phenylacetyl)amino)-1-piperidinyl)carbonyl) oxy)phenyl)propanoic acid;

(2S)-3-(4-(((4-((2-Cyclohexylacetyl)amino)-1-piperidinyl)carbonyl) oxy)phenyl)-2-(((2S)-2-((2-(2-cyclohexylphenoxy)acetyl)amino)-4-methyl pentanoyl)amino)propanoic acid;

and salts and solvates thereof.

40. A compound of formula (I) which is:

(2S)-2-(((2S)-2-((2-(2-Iodophenoxy)acetyl)amino)-4-methyl pentanoyl)amino)-3-(4-((4-morpholinylcarbonyl)oxy)phenyl)propanoic acid;

(2S)-2-(((2S)-2-((2-[2-(Tert-butyl)phenoxy]acetyl)amino)-4-methyl pentanoyl)amino)-3-(4-((4-morpholinylcarbonyl)oxy)phenyl)propanoic acid;

(2S)-3-(4-(((4-Acetyl-1-piperazinyl)carbonyl)oxy)phenyl)-2-(((2S)-2-((2-[2-(tert-butyl)phenoxy]acetyl)amino)-4-methylpentanoyl)amino)propanoic acid;

(2S)-2-(((2S)-2-((2-(2-Cyclohexylphenoxy)acetyl)amino)-4-methyl pentanoyl)amino)-3-(4-((4-morpholinylcarbonyl)oxy)phenyl)propanoic acid;

(2S)-2-(((2S)-2-((2-[2-(Tert-butyl)phenoxy]acetyl)amino)-4-methyl pentanoyl)amino)-3-(4-(((4-((2-phenylacetyl)amino)-1-piperidinyl)carbonyl) oxy) phenyl)propanoic acid;

(2S)-3-(4-(((4-Benzoyl-1-piperazinyl)carbonyl)oxy)phenyl)-2-(((2S)-2-((2-[2-(tert-butyl)phenoxy]acetyl)amino)-4-methylpentanoyl)amino)propanoic acid;

(2S)-3-(4-(((4-Acetyl-1-piperazinyl)carbonyl)oxy)phenyl)-2-(((2S)-2-
 [(dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methylpentanoyl)amino)propanoic acid;
 (2S)-2-(((2S)-2-((2-[2-(Tert-butyl)phenoxy]acetyl)amino)-4-methylpentanoyl)amino)-
 3-[4-(((4-(2-furoyl)-1-piperazinyl)carbonyl)oxy)phenyl]propanoic acid;
 (2S)-2-(((2S)-2-[(Dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methylpentanoyl)amino)-
 3-[4-(((4-(2-furoyl)-1-piperazinyl)carbonyl)oxy)phenyl]propanoic acid;
 (2S)-3-(4-(((4-Benzoyl-1-piperazinyl)carbonyl)oxy)phenyl)-2-(((2S)-4-methyl-2-[[2-(2-
 methylphenoxy)acetyl]amino]pentanoyl)amino)propanoic acid;
 (2S)-3-(4-(((4-Benzoyl-1-piperazinyl)carbonyl)oxy)phenyl)-2-(((2S)-2-
 [(dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methylpentanoyl)amino)propanoic acid;
 and salts and solvates thereof.

41. A compound of formula (I) which is:

(2S)-3-(4-(((4-Acetyl-1-piperazinyl)carbonyl)oxy)phenyl)-2-(((2S)-4-methyl-2-[[2-(2-
 methylphenoxy)acetyl]amino]pentanoyl)amino)propanoic acid;
 (2S)-3-[4-(((4-(Aminocarbonyl)-1-piperidinyl)carbonyl)oxy)phenyl]-2-(((2S)-2-
 [(dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methylpentanoyl)amino)propanoic acid;
 (2S)-3-[4-(((4-(Aminocarbonyl)-1-piperidinyl)carbonyl)oxy)phenyl]-2-(((2S)-2-((2-[2-
 (tert-butyl)phenoxy]acetyl)amino)-4-methylpentanoyl)amino)propanoic acid;
 (2S)-2-(((2S)-4-Methyl-2-[[2-(2-methylphenoxy)acetyl]amino]pentanoyl)amino)-3-[4-
 [(4-morpholinylcarbonyl)oxy]phenyl]propanoic acid;
 (2S)-3-[4-(((4-(Aminocarbonyl)-1-piperidinyl)carbonyl)oxy)phenyl]-2-(((2S)-2-[[2-(2-
 benzoylphenoxy)acetyl]amino]-4-methylpentanoyl)amino)propanoic acid;
 (2S)-2-(((2S)-2-((2-[4-(Aminocarbonyl)phenoxy]acetyl)amino)-4-
 methylpentanoyl)amino)-3-[4-(((4-(aminocarbonyl)-1-piperidinyl)carbonyl)oxy)
 phenyl]propanoic acid;
 and salts and solvates thereof.

42. A compound of formula (I) which is:

(2S)-3-[4-(((4-(Aminocarbonyl)-1-piperidinyl)carbonyl)oxy)phenyl]-2-(((2S)-4-methyl-2-
 [[2-(2-methylphenoxy)acetyl]amino]pentanoyl)amino)propanoic acid or a salt or
 solvate thereof.

43. A compound of formula (I) according to claim 42 which is:

(2S)-3-[4-(((4-(Aminocarbonyl)-1-piperidinyl)carbonyl)oxy)phenyl]-2-(((2S)-4-methyl-2-
 [[2-(2-methylphenoxy)acetyl]amino]pentanoyl)amino)propanoic acid potassium salt
 or a solvate thereof.

44. A pharmaceutical composition comprising a compound of formula (I) as
 defined in claim 29 or a pharmaceutically acceptable salt or solvate thereof in
 admixture with one or more pharmaceutically acceptable diluents or carriers.


45. A pharmaceutical composition comprising a compound of formula (I) according to claim 29 or a physiologically acceptable salt or solvate thereof in combination together with a long acting β_2 adrenergic receptor agonist.

46. A compound of formula (I) as defined in claim 29 or a pharmaceutically acceptable salt or solvate thereof for use as a pharmaceutical.

47. A method of treatment or prophylaxis of inflammatory diseaseseg. asthma which comprises administering to a patient an effective amount of a compound of formula (I) as defined in claim 29 or a pharmaceutically acceptable salt or solvate thereof.

48. A process for preparation of a compound of formula (I) as defined in claim 29 which comprises


(a) hydrolysis of a carboxylic acid ester of formula (II)



wherein R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are as defined in claim 29 and R is a group capable of forming a carboxylic acid ester; or


(b) deprotecting a compound of formula (I) which is protected.

49. A compound of formula (II)




wherein R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are as defined in claim 29 and R is a group capable of forming a carboxylic acid ester.

50. A compound of formula (VI)




wherein P_1 represents Boc, R^4 , R^5 and R^6 are as defined in claim 29, and R represents a group capable of forming a carboxylic acid ester.

51. A compound of formula (VII)




wherein P_1 represents Boc, R^1 , R^2 , R^4 , R^5 and R^6 are as defined in claim 29, and R represents a group capable of forming a carboxylic acid ester.

52. A compound of formula (VIII)



wherein R^1 , R^2 , R^4 , R^5 and R^6 are as defined in claim 29, HX is a hydrohalic acid and R represents a group capable of forming a carboxylic acid ester.

53. A compound of formula (XIII)



wherein R^4 , R^5 and R^6 are as defined in claim 29 and R' represents a hydroxy functionalised polystyrene resin.